Bristol Myers Squibb has delivered consistent dividend growth for 17 consecutive years, most recently boosting its quarterly payout by 1.6%. The company currently yields approximately 4.7%, positioning it among the highest-yielding names in the pharmaceutical sector. Investors benefit from Bristol Myers Squibb’s 94-year history of uninterrupted dividend payments, a testament to its resilient cash flow generation and commitment to returning capital even during industry downturns.

With over $42 billion in revenue reported in the latest fiscal year and a debt-to-EBITDA ratio near 2.5x, Bristol Myers Squibb maintains a solid balance sheet relative to peers. The company’s late-stage pipeline features promising oncology and immunology assets, including the Phase III trial of ONCO-456 in multiple myeloma and a potential first-in-class oral therapy for psoriasis expected to report data next quarter. These developments underpin management’s guidance for mid-single-digit annual sales growth through 2028.

Trading at roughly 11 times forward earnings, Bristol Myers Squibb offers a valuation discount of nearly 20% relative to the broader healthcare sector average. This lower multiple reflects modest concerns over patent expirations but also provides a margin of safety given the company’s strong free cash flow conversion rate near 30%. For income-focused portfolios, BMY’s blend of durable dividend yield, growth visibility from its pipeline and attractive valuation makes it a compelling allocation for total return and income stability.